{
    "ticker": "IRRXW",
    "name": "Imunon, Inc.",
    "description": "Imunon, Inc. is a biotechnology company focused on the development of innovative therapeutic solutions for patients with cancer and infectious diseases. Established in 2005, the company is committed to advancing its proprietary technologies to improve patient outcomes. Imunon's lead product candidates include therapeutic vaccines and immune-modulating agents that aim to harness the power of the immune system to fight disease. The company's research and development efforts are centered around enhancing the efficacy of existing treatments and discovering new modalities that can elicit robust immune responses. Imunon is particularly recognized for its work in the area of oncolytic viruses and its proprietary platform technologies that target cancer cells selectively while minimizing damage to healthy tissue. The company collaborates with various academic institutions and industry partners to expedite the development of its therapeutic candidates. Imunon's mission is to provide novel treatment options that offer hope to patients and enhance their quality of life, reflecting its dedication to innovation and excellence in the field of oncology and immunotherapy.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Malvern, Pennsylvania, USA",
    "founded": "2005",
    "website": "https://www.imunon.com",
    "ceo": "William D. Schwieterman",
    "social_media": {
        "twitter": "https://twitter.com/imunoninc",
        "linkedin": "https://www.linkedin.com/company/imunon/"
    },
    "investor_relations": "https://www.imunon.com/investors/",
    "key_executives": [
        {
            "name": "William D. Schwieterman",
            "position": "CEO"
        },
        {
            "name": "Kathy D. Pugh",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Vaccines",
            "products": [
                "IMUN-010",
                "IMUN-020"
            ]
        },
        {
            "category": "Immune Modulators",
            "products": [
                "IMUN-030"
            ]
        }
    ],
    "seo": {
        "meta_title": "Imunon, Inc. | Innovative Biotechnology Solutions for Cancer",
        "meta_description": "Explore Imunon, Inc., a biotechnology company focused on developing innovative therapies for cancer and infectious diseases. Learn about its mission, products, and impact on patient care.",
        "keywords": [
            "Imunon",
            "Biotechnology",
            "Cancer Treatment",
            "Immunotherapy",
            "Therapeutic Vaccines"
        ]
    },
    "faq": [
        {
            "question": "What is Imunon known for?",
            "answer": "Imunon is known for developing innovative therapeutic solutions for cancer and infectious diseases."
        },
        {
            "question": "Who is the CEO of Imunon?",
            "answer": "William D. Schwieterman is the CEO of Imunon, Inc."
        },
        {
            "question": "Where is Imunon headquartered?",
            "answer": "Imunon is headquartered in Malvern, Pennsylvania, USA."
        },
        {
            "question": "What are Imunon's main products?",
            "answer": "Imunon's main products include therapeutic vaccines and immune modulators, such as IMUN-010 and IMUN-030."
        },
        {
            "question": "When was Imunon founded?",
            "answer": "Imunon was founded in 2005."
        }
    ],
    "competitors": [
        "MRNA",
        "BNTX",
        "NVAX",
        "PFE"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "CELG",
        "REGN"
    ]
}